drugset / Trial / NCT01109615
Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations
FactorialOpen-labelTreatment
Summary
This study aims to investigate the efficacy and safety of the combination of pemetrexed and gemcitabine in heavily pre-treated, chemotherapy resistant colorectal cancer patients with KRAS mutations.
Timeline
- Start
- 2010-04
- Primary completion
- 2011-08
- Completion
- 2012-03
Outcome
Outcome not reported
Stopped: “Lacking effect of treatment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Pemetrexed | Small molecule | 400 mg/m2 | — |